Source
finimize
What's going on here?
BofA Securities just got more cautious on Alnylam’s heart-drug story, trimming its peak sales view to $11.8 billion and cutting its price target to $410.
What does this mean?
BofA, a major US bank, thinks Alnylam’s next quarterly update could do more than set a short-term tone: it may help investors pin down where 2026 revenue lands inside management’s guidance, and whether that range tightens again. The firm still sees a big market for transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where a misfolded protein builds up in the heart, but it wants more proof on how competition and insurers will shape long-run demand.
News Url